Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093158 · ClinicalTrials.gov registry record · Phase 3
Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)
A Phase 3 study, sponsored by The Medicines Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 13,800
- Enrollment target
NCT00093158: Completed Phase 3 study, sponsored by The Medicines Company.
NCT00093158 is a Phase 3 study that has completed, run by The Medicines Company. The registered enrollment target is 13,800 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1690% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00093158, a Phase 3 study, has completed, sponsored by The Medicines Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13,800 participants
- Enrollment target
Study Summary
The purpose of this study is to show that, when compared with heparin (enoxaparin or unfractionated heparin) and routine GPIIb/IIIa inhibition (either started upfront or at the time of percutaneous coronary intervention \[PCI\]; Arm A): 1. Bivalirudin with routine GPIIb/IIIa inhibition (either started upfront or at the time of PCI; Arm B) provides non-inferior or superior overall clinical outcomes and 2. Bivalirudin alone (Arm C) reduces clinically significant bleeding. An important secondary objective for this comparison is to show that bivalirudin is not inferior for ischemic complications.
Interventions
- DRUG Angiomax (bivalirudin) anticoagulant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,800 participants |
| Start Date | 2003-08 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
What the finished NCT00093158 record still lists
NCT00093158 is an interventional study that assigns participants to a tested intervention. Its 13,800 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1690% higher).
The record links to 0 conditions, and to 1 intervention - of which Angiomax (bivalirudin) anticoagulant is the first listed.
NCT00093158 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00093158 about?
NCT00093158 is a clinical study titled "Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)". The purpose of this study is to show that, when compared with heparin (enoxaparin or unfractionated heparin) and routine GPIIb/IIIa inhibition (either started upfront or at the time of percutaneous coronary intervention \[PCI\]; Arm A): 1. Bivalirudin with routine GPIIb/IIIa inhibition (either star...
What is the current status of trial NCT00093158?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13,800 participants. The study started on 2003-08. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00093158?
The interventions under investigation include: Angiomax (bivalirudin) anticoagulant (DRUG).
Who is sponsoring clinical trial NCT00093158?
This trial is sponsored by The Medicines Company, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00093158's enrollment target sits among peer trials
13,800 17th of 2000 higher than 1,984 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06058767 · 13,764 participants · NA
Preschool Hearing Screening
- NCT05141396 · 13,400 participants · NA
Telehealth-Enabled, Real-time Audit and Feedback for Clinician AdHerence (TEACH)
- NCT05591066 · 14,400 participants · NA
The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now
- NCT05359016 · 14,600 participants · NA
Evaluating Innovative Technologies and Approaches to Addressing Cervical Cancer in Gaza and Maputo Cidade Provinces in Mozambique
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia